These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 11554957

  • 1. Effectiveness of nasal sumatriptan in 5- to 12-year-old children.
    Hershey AD, Powers SW, LeCates S, Bentti AL.
    Headache; 2001; 41(7):693-7. PubMed ID: 11554957
    [Abstract] [Full Text] [Related]

  • 2. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types.
    Ashford E, Salonen R, Saiers J, Woessner M.
    Cephalalgia; 1998 Jun; 18(5):273-7. PubMed ID: 9673807
    [Abstract] [Full Text] [Related]

  • 3. Parental satisfaction with sumatriptan nasal spray in childhood migraine.
    Pakalnis A, Kring D, Paolicchi J.
    J Child Neurol; 2003 Nov; 18(11):772-5. PubMed ID: 14696905
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
    Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M.
    Neurology; 1997 Nov; 49(5):1225-30. PubMed ID: 9371898
    [Abstract] [Full Text] [Related]

  • 6. Sumatriptan. An updated review of its use in migraine.
    Perry CM, Markham A.
    Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
    [Abstract] [Full Text] [Related]

  • 7. Symptomatic treatment of migraine in children: a systematic review of medication trials.
    Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW.
    Pediatrics; 2005 Aug; 116(2):e295-302. PubMed ID: 16061583
    [Abstract] [Full Text] [Related]

  • 8. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations.
    Weidmann E, Unger J, Blair S, Friesen C, Hart C, Cady R.
    Clin Ther; 2003 Jan; 25(1):235-46. PubMed ID: 12637123
    [Abstract] [Full Text] [Related]

  • 9. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.
    Rothner AD, Winner P, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M.
    Clin Ther; 2000 Dec; 22(12):1533-46. PubMed ID: 11192144
    [Abstract] [Full Text] [Related]

  • 10. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L.
    CNS Drugs; 2005 Dec; 19(2):125-36. PubMed ID: 15697326
    [Abstract] [Full Text] [Related]

  • 11. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.
    Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, Siffert J.
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [Abstract] [Full Text] [Related]

  • 12. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine.
    Natarajan S, Jabbour JT, Webster CJ, Richardson MS.
    Headache; 2004 Jun; 44(10):969-77. PubMed ID: 15546259
    [Abstract] [Full Text] [Related]

  • 13. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P, Rothner AD, Wooten JD, Webster C, Ames M.
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [Abstract] [Full Text] [Related]

  • 14. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J.
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [Abstract] [Full Text] [Related]

  • 15. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
    Géraud G, Valette C.
    Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M.
    Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
    [Abstract] [Full Text] [Related]

  • 17. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
    Winner P, Ricalde O, Le Force B, Saper J, Margul B.
    Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
    [Abstract] [Full Text] [Related]

  • 18. Clinical pharmacokinetics of intranasal sumatriptan.
    Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T.
    Clin Pharmacokinet; 2002 Feb; 41(11):801-11. PubMed ID: 12190330
    [Abstract] [Full Text] [Related]

  • 19. How does sumatriptan nasal spray perform in clinical practice?
    Dahlöf CG, Boes-Hansen S, Cederberg CG, Hardebo JE, Henriksson A.
    Cephalalgia; 1998 Jun; 18(5):278-82. PubMed ID: 9673808
    [Abstract] [Full Text] [Related]

  • 20. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger.
    Hämäläinen M, Jones M, Loftus J, Saiers J.
    Int J Clin Pract; 2002 Nov; 56(9):704-9. PubMed ID: 12469987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.